Sean T H Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4235711/publications.pdf Version: 2024-02-01



SEAN THLUL

#	Article	IF	CITATIONS
1	Transfusion reactions associated with <scp>COVID</scp> â€19 convalescent plasma therapy for <scp>SARSâ€CoV</scp> â€2. Transfusion, 2021, 61, 78-93.	1.6	17
2	Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
3	Convalescent plasma in patients hospitalised with COVID-19. Lancet, The, 2021, 397, 2024-2025.	13.7	18
4	The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2021, 96, 1262-1275.	3.0	129
5	First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes. Science Translational Medicine, 2021, 13, .	12.4	38
6	Development of a Macrophage-Based ADCC Assay. Vaccines, 2021, 9, 660.	4.4	7
7	Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. Immunity, 2020, 53, 1230-1244.e5.	14.3	61
8	A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2020, 222, 1629-1634.	4.0	27
9	Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nature Medicine, 2020, 26, 1708-1713.	30.7	405
10	Treatment with convalescent plasma in solid organ transplant recipients with COVIDâ€19: Experience at large transplant center in New York City. Clinical Transplantation, 2020, 34, e14089.	1.6	28
11	Convalescent Plasma for the Treatment of Severe COVIDâ€19 Infection in Cancer Patients. Cancer Medicine, 2020, 9, 8571-8578.	2.8	43
12	A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Medicine, 2020, 26, 1033-1036.	30.7	1,678
13	A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. Npj Vaccines, 2019, 4, 31.	6.0	40
14	Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. Journal of Virology, 2019, 93, .	3.4	21
15	Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. Journal of Clinical Investigation, 2018, 128, 4992-4996.	8.2	51
16	An electronic antimicrobial stewardship intervention reduces inappropriate parenteral antibiotic therapy. Infection Control and Hospital Epidemiology, 2018, 39, 1396-1397.	1.8	0
17	Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. Journal of Virology, 2018, 92, .	3.4	24
18	Synaptic vesicle-like lipidome of human cytomegalovirus virions reveals a role for SNARE machinery in virion egress. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12869-12874.	7.1	99